Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Web-Based Return of Individual Patient-Reported Outcome Results Among Patients With Lymphoma: Randomized Controlled Trial.
Oerlemans S, Arts LPJ, Kieffer JM, Prins J, Hoogendoorn M, van der Poel M, Koster A, Lensen C, Stevens WBC, Issa D, Pruijt JFM, Oosterveld M, van der Griend R, Nijziel M, Tick L, Posthuma EFM, van de Poll-Franse LV. Oerlemans S, et al. Among authors: posthuma efm. J Med Internet Res. 2021 Dec 14;23(12):e27886. doi: 10.2196/27886. J Med Internet Res. 2021. PMID: 34904948 Free PMC article. Clinical Trial.
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Kersting S, Dubois J, Nasserinejad K, Dobber JA, Mellink C, van der Kevie-Kersemaekers AF, Evers LM, de Boer F, Koene HR, Schreurs J, van der Klift M, Velders GA, van der Spek E, van der Straaten HM, Hoogendoorn M, van Gelder M, Posthuma EFM, Visser HPJ, Houtenbos I, Idink CAM, Issa DE, Dompeling EC, van Zaanen HCT, Veelken H, Levenga H, Tick LW, Terpstra WE, Tonino SH, Boyer M, Mobasher M, Levin MD, Kater AP; HOVON CLL study group. Kersting S, et al. Among authors: posthuma efm. Lancet Haematol. 2022 Mar;9(3):e190-e199. doi: 10.1016/S2352-3026(22)00034-5. Lancet Haematol. 2022. PMID: 35240075 Clinical Trial.
Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989-2018.
Durmaz M, Visser O, Posthuma EFM, Brouwer RE, Issa DE, de Jong D, Lam KH, Blijlevens NMA, Zijlstra JM, Chamuleau MED, Lugtenburg PJ, Kersten MJ, Dinmohamed AG. Durmaz M, et al. Among authors: posthuma efm. Blood Cancer J. 2022 Mar 9;12(3):38. doi: 10.1038/s41408-022-00637-1. Blood Cancer J. 2022. PMID: 35264598 Free PMC article.
Persistent symptoms of fatigue, neuropathy and role-functioning impairment among indolent non-Hodgkin lymphoma survivors: A longitudinal PROFILES registry study.
Ekels A, van de Poll-Franse LV, Posthuma EFM, Kieffer J, Issa DE, Koster A, Nijziel MR, Pruijt JHFM, Stevens WBC, Tick LW, Oerlemans S. Ekels A, et al. Among authors: posthuma efm. Br J Haematol. 2022 Jun;197(5):590-601. doi: 10.1111/bjh.18139. Epub 2022 Apr 2. Br J Haematol. 2022. PMID: 35365860
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
Raa DGT, van der Straten L, van Gelder M, Kersting S, Levin MD, Mous R, van der Straaten HM, Nijziel MR, van der Spek E, Posthuma EFM, Visser HPJ, van der Klift M, de Heer K, Bellido M, Doorduijn JK, Bruns AHW, Raijmakers RAP, Kater AP; HOVON CLL study group. Raa DGT, et al. Among authors: posthuma efm. Leuk Lymphoma. 2022 Oct;63(10):2276-2289. doi: 10.1080/10428194.2022.2084731. Epub 2022 Jun 23. Leuk Lymphoma. 2022. PMID: 35737364
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
van der Straten L, Stege CAM, Kersting S, Nasserinejad K, Dubois J, Dobber JA, Mellink CHM, van der Kevie-Kersemaekers AF, Evers LM, de Boer F, Koene HR, Schreurs J, van der Klift M, Velders GA, van der Spek E, van der Straaten HM, Hoogendoorn M, van Gelder M, Posthuma EFM, Visser HPJ, Houtenbos I, Idink CAM, Issa DE, Dompeling EC, van Zaanen HCT, Veelken JH, Levenga H, Tick LW, Terpstra WE, Tonino SH, Westerweel PE, Langerak AW, Kater AP, Levin MD. van der Straten L, et al. Among authors: posthuma efm. Blood. 2023 Sep 28;142(13):1131-1142. doi: 10.1182/blood.2023020195. Blood. 2023. PMID: 37363833
No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study.
Geerdes EE, Durmaz M, Lugtenburg PJ, Chamuleau MED, Visser O, Issa DE, Brouwer RE, Posthuma EFM, Zijlstra JM, Kersten MJ, Dinmohamed AG. Geerdes EE, et al. Among authors: posthuma efm. Blood Adv. 2023 Sep 12;7(17):4869-4873. doi: 10.1182/bloodadvances.2023010480. Blood Adv. 2023. PMID: 37389820 Free PMC article. No abstract available.
67 results